← Leaderboards
Keith Booher
Zymo Research Corporation
$1,522,601
Attributed
$3,761,579
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,761,579 · 2
By mechanism
R42$3,536,579 · 1
R41$225,000 · 1
Top collaborators
- Shaoling Huang5 shared
- Wei Guo3 shared
Others in their field
Other Emerging Leaders on “Biological Markers”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,644,754
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$206,375,181
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,483,553
- Leonard Freedmand · Leidos Biomedical Research, Inc.$64,555,721
- Yunda Huang · Fred Hutchinson Cancer Center$54,118,126
- Susan Abushakra · Alzheon, Inc.$50,765,244
Research focus
Biological MarkersEpigenetic MarkerSmall Business Technology Transfer ResearchXenonStrokeInjuryEpigenetic ProcessProtocols DocumentationIschemic StrokeUniversitiesHealth SciencesTexasNeurologic DysfunctionsPathologicAcuteCytoprotectionLiposomesBrainPharmacologic SubstanceAcute StrokeFormulationPreparationDrug KineticsDose
Grant awards (5)
A Novel Xenon Delivery Platform for Cerebroprotection During Stroke$980,725
R42 · FY2025 · NS · contact PI
A Novel Xenon Delivery Platform for Cerebroprotection During Stroke$631,721
R42 · FY2024 · NS · contact PI
Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment$841,419
R42 · FY2022 · NS · contact PI
Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment$1,082,714
R42 · FY2021 · NS · contact PI
Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment$225,000
R41 · FY2017 · NS · contact PI